SLC22A6 and chronic kidney disease: Our CKD‐PBPK model was able to recapitulate the changes in adefovir AUC and Cmax with disease progression (Figure 4), thus further emphasizing the importance of implementing the additional 50% decline in OAT1 activity beyond the deterioration of GFR in severe CKD.